The DOI matches its Crossref record.
Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure
Open accessAbstract
BACKGROUND: Patients with acute renal failure (ARF) have high morbidity and mortality rates, particularly if they have serious comorbid conditions. Several studies indicate that in rats with ARF caused by ischemia or certain nephrotoxins, insulin-like growth factor-I (IGF-I) enhances the recovery of renal function and suppresses protein catabolism. METHODS: Our objective was to determine whether injections of recombinant human IGF-I (rhIGF-I) would enhance the recovery of renal function and is safe in patients with ARF. The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals. Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients). The most common causes of ARF in the rhIGF-I and placebo groups were, respectively, sepsis (37 and 35% of patients) and hypotension or hemodynamic shock (42 and 27% of patients). At baseline, the mean (+/- SD) APACHE II scores in the rhIGF-I and placebo-treated groups were 24 +/- 5 and 25 +/- 8, respectively. In the rhIGF-I and placebo groups, the mean (median) urine volume and urinary iothalamate clearances (glomerular filtration rate) were 1116 +/- 1037 (887) and 1402 +/- 1183 (1430) ml/24 hr and 6.4 +/- 5.9 (4.3) and 8.7 +/- 7.2 (4.4) ml/min and did not differ between the two groups. Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 microgram/kg desirable body weight, or placebo for up to 14 days. Injections were started within six days of the onset of ARF. The primary end-point was a change in glomerular filtration rate from baseline. Other end points included changes from baseline in urine volume, creatinine clearance and serum urea, creatinine, albumin and transferrin, frequency of hemodialysis or ultrafiltration, and mortality rate. RESULTS: During the treatment period, which averaged 10.7 +/- 4.1 and 10.6 +/- 4.5 days in the rhIGF-I and placebo groups, there were no differences in the changes from baseline values of the glomerular filtration rate, creatinine clearance, daily urine volume, or serum urea nitrogen, creatinine, albumin or transferrin. In patients who did not receive renal replacement therapy, there was also no significant difference in serum creatinine and urea between the two groups. Twenty patients in the rhIGF-I group and 17 placebo-treated patients underwent dialysis or ultrafiltration. Twelve rhIGF-I-treated patients and 12 placebo-treated patients died during the 28 days after the onset of treatment. CONCLUSIONS: rhIGF-I does not accelerate the recovery of renal function in ARF patients with substantial comorbidity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)
Kellum, J. A., Lameire, N., & for the KDIGO AKI Guideline Work Group (2013) · Critical Care · doi:10.1186/cc11454 · Cited by 2,827
Spectrum of acute renal failure in the intensive care unit: The PICARD experience
Mehta, R. L., Pascual, M. T., Soroko, S., Savage, B. R., Himmelfarb, J., Ikizler, T. A., Paganini, E. P., & Chertow, G. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00927.x · Cited by 962
Diagnosis, Epidemiology and Outcomes of Acute Kidney Injury
Waikar, S. S., Liu, K. D., & Chertow, G. M. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05191107 · Cited by 533
Emerging Biomarkers of Acute Kidney Injury
Devarajan, P. (2007) · Contributions to Nephrology · doi:10.1159/000102085 · Cited by 276
Ho, J., Tangri, N., Komenda, P., Kaushal, A., Sood, M., Brar, R., Gill, K., Walker, S., MacDonald, K., Hiebert, B. M., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.06.018 · Cited by 269
Metadata
- Authors
- Hirschberg, R., Kopple, J., Lipsett, P., Benjamin, E., Minei, J., Albertson, T., Munger, M., Metzler, M., Zaloga, G., Murray, M., Lowry, S., Conger, J., Mckeown, W., O'Shea, M., Baughman, R., Wood, K., Haupt, M., Kaiser, R., Simms, H., Warnock, D., Summer, W., Hintz, R., Myers, B., Haenftling, K., Capra, W., Pike, M., & Guler, H.-P.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 1999-06
- Volume
- 55
- Issue
- 6
- Pages
- 2423-2432
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2048489506
- Cited by
- 305
- References
- 0
- FWCI
- 10.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. https://app.cochat.ai/papers/10.1046/j.1523-1755.1999.00463.x
- The paper
- Hirschberg, R., Kopple, J., Lipsett, P., Benjamin, E., Minei, J., Albertson, T., Munger, M., Metzler, M., Zaloga, G., Murray, M., Lowry, S., Conger, J., Mckeown, W., O'Shea, M., Baughman, R., Wood, K., Haupt, M., Kaiser, R., Simms, H., . . . Guler, H.-P. (1999). Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney International. https://doi.org/10.1046/j.1523-1755.1999.00463.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.